p53 antisense agent and method

Details p53 antisense agent and method p53 antisense agent and method

1999-10-22

2002-04-02

Wang, Andrew (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S091100, C435S375000, C435S455000, C536S023100, C536S024500, C536S025300, C536S031000

Reexamination Certificate

active

06365577

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to antisense agents and methods for the treatment of disease states which are characterized by induction of p53. Such conditions include proliferative cell disorders, such as cancer, restenosis, and psoriasis, and hypoxic states induced by ischemic attacks such as stroke.
REFERENCES
Adhad, N. et al.,
Biochem. Biophys. Res. Commun
. 247:294-301 (1998).
Agrawal, S. et al.,
Proc. Natl. Acad. Sci. USA
87(4):1401-5 (1990).
Arora, V., Ph.D. Dissertation, Dep. Pharmacol., Univ. Nebraska Coll. Med. (1998).
Assy, N. et al., “Use of proliferating cell nuclear antigen as a marker of liver regeneration after partial hepatectomy in rats,”
J Lab Clin Med
131(3):251-256 (1998).
Bonham, M. A. et al.,
Nucleic Acids Res
. 23(7):1197-1203 (1995).
Boudvillain, M. et al.,
Biochemistry
36(10):2925-31 (1997).
Chen, J.-K. et al.,
Nucleic Acids Res
. 23:2661-8 (1994).
Cross, S. M. et al.,
Science
267 (5202) p1353-6 (1995).I
Edelman, E. R. et al.,
Circ. Res
. 76(2):176-182 (1995).
Farrell, C. L. et al.,
Antisense Res. and Dev
. 5:175-183 (1995).
Gambacorti-Passerini, C. et al.,
Blood
88(4):1411-7 (1996).
Gee, J. E. et al.,
Antisense
&
Nucleic Acid Drug Dev
. 8:103-111 (1998).
Giles, R. V. et al.,
Anticancer Drug Des
. 8(1):33-51 (1993).
Graeber, T. G. et al.,
Mol. Cell Biol
. 14(9):6264-77 (1994).
Grisham, J. W. et al., “Cell cycle and chemical carcinogenesis,”
Surv. Synth. Pathol. Res
. 9-66 (1983).
Gryaznov, S. M. et al.,
Proc. Natl. Acad. Sci. USA
92:5798-5802 (1995).
Hanvey, J. C. et al.,
Science
258:1481-85 (1992).
Hartwell, L. H. and Kastan, M. B. “Cell cycle control and cancer,”
Science
266:1821-28 (1994).
Higgins, G. M. and Anderson, R. M.
Arch. Pathol
. 12:186. (1931).
Horiguchi et al.,
Takeda Kenyushoho
55:149-159 (1996).
Johansson, H. E. et al.,
Nucleic Acids Res
. 22:4591-8 (1994).
Kanoh et al.,
Bioorg. Chem. Lett
. 7:2847 (1997).
Kastan, M. B. et al.,
Cell
71: 587-97. (1992).
Khooustov, V. I., et al.,
Lab. Invest
. 73:118-127 (1995).
Knudsen, H. and Nielsen, P. E.,
Nucleic Acids Res
. 24(3):494-500 (1996).
Koch et al.,
Biochem. Biophys. Res. Commun
. 225:531-536 (1996).
Levine, A. J. “p53, The cellular gatekeeper for growth and division,”
Cell
88:323-331 (1997).
Li, Y. et al.,
Brain Res
765 (2) p301-12 (1997).
Lu, X. and Lane, D. P.,
Cell
75(4):765-78 (1993).
Magnelli, L. et al.,
Biochem Mol Med
62(1):3-10 (1997).
Messmer, U. K. et al., “p53 Expression in nitric oxide-induced apoptosis”,
FEBS Lett
535(l):23-6 (1994).
Nelson, W. G. and Kastan, M. B.,
Mol. Cell Biol
. 14: 1815-1823 (1994).
Nielsen, P. E. et al.,
Science
254:1497-1503 (1991).
Raafat, A. M. et al.,
Shock Sep
8 (3) p186-92 (1997).
Rininger, J. A. et al. “Time course comparison of cell-cycle protein expression following partial hepatectomy and WY 14,643-induced hepatic cell proliferation in F344 rats.”
Carcinogenesis
18(5):935-41 (1997).
Rosenberg, R. D. et al., U.S. Pat. No. 5,593,974 (1997).
Russell, K. J. et al.,
Int. J. Radiat. Oncol. Biol. Phys
. 36(1099-1106 (1996).
Russo, A. et al.,
Cancer Treatment Reports
, 69(11):1293-96 (1985).
Sato, F. et al.,
Biochem. Biophys. Res. Commun
. 204:578-584 (1994).
Sedlacek et al.,
Int. J. Oncol
. 9:1143-1168 (1996).
Shu, M. et al.,
Apoptosis
2:263-470 (1997).
Soini, T. et al.,
Br. J. Dermatol
. 131(4):514-20 (1994).
Speir, E. et al.,
Scand. J. Infect. Dis. Suppl
. 99:78-81 (1995).
Swe, M. et al.,
Biochem. Biophys. Res. Commun
. 236:594-598 (1997).
Tadini, G. et al.,
Acta Derm. Venereol Suppl
. 146:33-35 (1989).
Van Dolah, F. M. et al.,
J. Cell Physiol
. 166:49-56 (1996).
Wagner, R. W. et al.,
Science
260:1510-13 (1993).
Waldman, T. et al., “Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
,” Nature
381:713-716 (1996).
Xiang, H. et al.,
J Neurosci
16 (21) p6753-65 (1996).
Zhang, M. and Raveche, E. S.,
Oncol Rep
5 (1) p23-30 (1998).
Zhu, W. Y. et al.,
Exp. Cell Res
. 2:463-470 (1997).
BACKGROUND OF THE INVENTION
The importance of p53 in cell proliferation is apparent from the observation that more than half of all human cancers display p53 mutations (Levine, 1997). An induction in p53 expression is observed in cells exposed to DNA alkylating agents, nitric oxide (Messmer, 1994), ionizing and ultraviolet irradiation (Lu and Lane, 1993), the restriction enzyme PvuII, which induces chromosome damage (Lu and Lane, 1993), and other agents capable of inducing DNA strand breaks (Nelson and Kastan, 1994). Ischemia/reperfusion (Raafat, 1997), models of epilepsy (Xiang, 1996), and hypoxia (Graeber, 1994) have also been demonstrated to induce p53. As shown herein and in previous studies (Rininger, 1997), p53 protein levels are also highly upregulated during the course of liver regeneration following partial hepatectomy, showing that damage of endogenous origin can also cause induction of p53 in vivo.
Roles for p53 have been postulated in cell cycle checkpoint activity, apoptosis, differentiation and DNA repair (Magnelli, 1997). Cell cycle checkpoints serve two important functions. One is to ensure that essential events in the cell cycle are completed before a subsequent event; the other is to provide more time for repair of damaged DNA before DNA replication and mitosis occur (Hartwell, 1994). The checkpoint activity of p53 occurs predominantly at the level of cells entering the S-phase (DNA synthesis) of the cell cycle (Kastan, 1992). G
2
-M checkpoint activity has also been reported for p53, due to its role as an upstream regulator of p21
waf−1
. In the absence of either protein, DNA-damaged cells arrest in a G
2
-like state, but then undergo additional S phases without intervening normal mitoses (M phase), leading to nuclear abnormalities, e.g. polyploidy, and culminating in apoptosis (Waldman,
SUMMARY OF THE INVENTION
The invention provides, in one aspect, methods and compositions for treating a disease state characterized by p53 induction in a mammalian subject. The method comprises administering to the subject, in a suitable pharmaceutical carrier, a pharmaceutically effective amount of an antisense agent having the base sequence SEQ ID NO: 1, identified as 5′-TCA GTC TGA GTC AGG CCC-3, or the base sequence SEQ ID NO:2, identified as 5′-CCC TGC TCC CCC CTG GCT CC-3′, where the antisense agent is a morpholino oligonucleotide, a peptide nucleic acid, a 2′-O-allyl or 2′-O-alkyl modified oligonucleotide, a N3′→P5′ phosphoramidate oligonucleotide, or a C-5-propyne pyrimidine-modified oligonucleotide. In a preferred embodiment, the antisense agent is a morpholino oligonucleotide, preferably having morpholino subunits joined by phosphorodiamidate backbone linkages. In another preferred embodiment, the antisense agent is a C-5-propyne pyrimidine-modified oligonucleotide.
The invention also includes compositions for use in treating such disease states. These compositions include antisense agents as described above, in a suitable pharmaceutical carrier.
In preferred applications of the method, the subject is a human subject. The disease state may be one which results from an ischemic or ischemic/reperfusive injury, such as stroke or the aftermath of organ transplant. Alternatively, the disease state may be cancer, in which case a preferred embodiment further comprises administering an agent effective to increase radical oxygen species at the cellular level. Such agents include radiosensitizing agents, ionizing radiation, a hyperbaric oxygen environment, and chemotherapeutic agents, such as certain anthracyclines or anthraquinones, which increase radical oxygen species at the cellular level.
For cancer treatment, the method may also include administering an agent effective to interfere with progression from the G
2
phase to the M phase of the cell cycle. Such agents include phosphokinase C (PKC) inhibitors, bis(chloroethyl)nitrosourea (BCNU), pentoxifylline, silymarin, staurosporine, phenylahistin, paclitaxel, retinoic acid, flavopiridol, methyl-2,5-dihydrocinnamate, herboxidiene, 9-nitrocamp

Affiliated with

Also associated with

Rating

p53 antisense agent and method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with p53 antisense agent and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and p53 antisense agent and method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2840330